About_editors 1..1 - Free

350 Mouton52. Purkins L, Wood N, Greenhalgh K, Allen MJ, Oliver SD. Voriconazole, a novel widespectrumtriazole: oral pharmacokinetics and safety. Br J Clin Pharmacol 2003; 56(suppl 1):10–16.53. Mar PIL. Label: voriconazole for injection, tablets, oral suspension. In: LAB-0271-12; 2005.54. Saad AH, DePestel DD, Carver PL. Factors influencing the magnitude and clinical significanceof drug interactions between azole antifungals and select immunosuppressants.Pharmacotherapy 2006; 26(12):1730–1744.55. Smith J, Safdar N, Knasinski V, et al. Voriconazole therapeutic drug monitoring. AntimicrobAgents Chemother 2006; 50(4):1570–1572.56. Courtney R, Sansone A, Smith W, et al. Posaconazole pharmacokinetics, safety, andtolerability in subjects with varying degrees of chronic renal disease. J Clin Pharmacol 2005;45(2):185–192.57. Courtney R, Wexler D, Radwanski E, Lim J, Laughlin M. Effect of food on the relativebioavailability of two oral formulations of posaconazole in healthy adults. Br J ClinPharmacol 2004; 57(2):218–222.58. Krishna G, Sansone-Parsons A, Martinho M, Kantesaria B, Pedicone L. Posaconazoleplasma concentrations in juvenile patients with invasive fungal infection. AntimicrobAgents Chemother 2007. In press.59. Georgopapadakou NH, Walsh TJ. Antifungal agents: chemotherapeutic targets and immunologicstrategies. Antimicrob Agents Chemother 1996; 40(2):279–291.60. National Committee for Clinical Laboratory Standards. Reference method for broth dilutionantifungal susceptibility testing of yeasts. M27-A2. Wayne: National Committee for ClinicalLaboratory Standards; 2002.61. Rodriguez-Tudela JL, Barchiesi F, Bille J, et al. Method for the determination of minimuminhibitory concentration (MIC) by broth dilution of fermentative yeasts. Clin MicrobiolInfect 2003; 9:I–VIII.62. Rodriguez-Tudela JL, Donnelly JP, Pfaller MA, et al. Statistical analyses of correlationbetween fluconazole MICs for Candida spp. assessed by standard methods set forth bythe European Committee on Antimicrobial Susceptibility Testing (E.Dis. 7.1) and CLSI(M27-A2). J Clin Microbiol 2007; 45(1):109–111.63. Espinel-Ingroff A, Barchiesi F, Cuenca-Estrella M, et al. International and multicentercomparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilitiesof Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole. J ClinMicrobiol 2005; 43(8):3884–3889.64. Mouton JW, Voss A, van Elzakker EPM, et al. Linezolid susceptibility of glycopeptideintermediatelysusceptible Staphylococcus aureus (GISA)—the Dutch experience. In: ECC-MID; 2003; Glasgow; 2003.65. Ribeiro da Matta VL, de Souza Carvalho Melhem M, Colombo AL, et al. Susceptibilityprofile to antifungal drugs of Pichia anomala isolated from patients presenting nosocomialfungemia 10.1128/AAC.01038-06. Antimicrob Agents Chemother 2007;AAC.01038–06.66. Odds FC, Vranckx L, Woestenborghs F. Antifungal susceptibility testing of yeasts: evaluationof technical variables for test automation. Antimicrob Agents Chemother 1995;39(9):2051–2060.67. Mouton JW, Vinks AA. PK-PD modelling of antibiotics in vitro and in vivo using bacterialgrowth and kill kinetics: the MIC versus stationary concentrations. Clinical Pharmacokinetics2005. In press.68. NCCLS. Development of In Vitro Susceptibility Testing Criteria and Quality ControlParameters; Approved Guideline-Second Edition. NCCLS document M23-A2. Wayne:NCCLS; 2001.69. Cormican MG, Pfaller MA. Standardization of antifungal susceptibility testing. J AntimicrobChemother 1996; 38(4):561–578.70. Rex JH, Pfaller MA, Walsh TJ, et al. Antifungal susceptibility testing: practical aspects andcurrent challenges. Clin Microbiol Rev 2001; 14(4):643–658, table of contents.71. Altman FP. Tetrazolium salts and formazans. Prog Histochem Cytochem 1976; 9(3):1–56.72. Meletiadis J, Verweij PE, TeDorsthorst DT, Meis JF, Mouton JW. Assessing in vitrocombinations of antifungal drugs against yeasts and filamentous fungi: comparison ofdifferent drug interaction models. Med Mycol 2005; 43(2):133–152.